Histopathologic classification of ANCA-associated glomerulonephritis.

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is the most common cause of rapidly progressive glomerulonephritis worldwide, and the renal biopsy is the gold standard for establishing the diagnosis. Although the prognostic value of the renal biopsy in ANCA-associated glomerulonephritis is widely recognized, there is no consensus regarding its pathologic classification. We present here such a pathologic classification developed by an international working group of renal pathologists. Our classification proposes four general categories of lesions: Focal, crescentic, mixed, and sclerotic. To determine whether these lesions have predictive value for renal outcome, we performed a validation study on 100 biopsies from patients with clinically and histologically confirmed ANCA-associated glomerulonephritis. Two independent pathologists, blinded to patient data, scored all biopsies according to a standardized protocol. Results show that the proposed classification system is of prognostic value for 1- and 5-year renal outcomes. We believe this pathologic classification will aid in the prognostication of patients at the time of diagnosis and facilitate uniform reporting between centers. This classification at some point might also provide means to guide therapy.

[1]  J. Stone,et al.  Correlation of Percentage of Normal Glomeruli with Renal Outcome in Wegener’s Granulomatosis , 2002, American Journal of Nephrology.

[2]  R. Wolterbeek,et al.  Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. , 2006, Journal of the American Society of Nephrology : JASN.

[3]  R. Falk,et al.  New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies , 2008, Current opinion in rheumatology.

[4]  A. Soleiman,et al.  Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  Lee Hebert,et al.  The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Journal of the American Society of Nephrology : JASN.

[6]  S. Adler,et al.  ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  H. E. Hansen,et al.  The Banff 97 working classification of renal allograft pathology. , 1999, Kidney international.

[8]  Emile de Heer,et al.  Immunopathological aspects of systemic vasculitis , 2009, Springer Seminars in Immunopathology.

[9]  D. Abramowicz,et al.  Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. , 2007, Journal of the American Society of Nephrology : JASN.

[10]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  V. D’Agati,et al.  Pauci-immune crescentic glomerulonephritis superimposed on diabetic glomerulosclerosis. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[12]  T. Dougan,et al.  Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. , 2004, Kidney international.

[13]  L. Bostad,et al.  Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  R. Falk,et al.  Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. , 1989, The American journal of pathology.

[15]  V. D’Agati,et al.  Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[16]  Kdoqi Disclaimer K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  P. van Paassen,et al.  Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  J. Hermans,et al.  Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. , 1999, Kidney international.

[19]  Agnes B Fogo,et al.  Pathologic classification of focal segmental glomerulosclerosis: a working proposal. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  H. Raspe,et al.  Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force , 2007, Annals of the rheumatic diseases.

[21]  H. V. van Houwelingen,et al.  An index for renal outcome in ANCA-associated glomerulonephritis. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  J. Jennette Rapidly progressive crescentic glomerulonephritis. , 2003, Kidney international.

[23]  R. Poveda,et al.  Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  R. Frederick,et al.  ANCA-associated glomerulonephritis : insights into etiology, pathogenesis, and prognosis , 2009 .

[25]  David Roth,et al.  A simplified equation to predict glomerular filtration rate from serum creatinine , 2000 .

[26]  Y. Tomino,et al.  Renal pathology of ANCA-related vasculitis: proposal for standardization of pathological diagnosis in Japan , 2008, Clinical and Experimental Nephrology.

[27]  J. Ioannidis,et al.  Clinicopathologic predictors of death and ESRD in patients with pauci-immune necrotizing glomerulonephritis. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  J. Hermans,et al.  The renal histopathology in systemic vasculitis: an international survey study of inter- and intra-observer agreement. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  S Senn,et al.  Repeated measures in clinical trials: simple strategies for analysis using summary measures. , 2000, Statistics in medicine.

[30]  R. Falk,et al.  Small-vessel vasculitis. , 1997, The New England journal of medicine.

[31]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[32]  H. V. van Houwelingen,et al.  Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. , 2002, Kidney international.

[33]  H. V. van Houwelingen,et al.  Long-term renal injury in ANCA-associated vasculitis: an analysis of 31 patients with follow-up biopsies. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  D. Jayne,et al.  Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. , 1990, Kidney international.

[35]  V. Tesar,et al.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. , 2003, The New England journal of medicine.

[36]  V. D’Agati,et al.  Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. , 2008, Clinical journal of the American Society of Nephrology : CJASN.